ARS Pharmaceuticals Launches “Get neffy on Us” Program To Expand Access For Needle-Free Allergy Treatment

ARS Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on helping at-risk patients manage severe allergic reactions, has introduced “Get neffy on Us,” a new program designed to improve access to its needle-free epinephrine product, neffy. The initiative removes the need for an in-person doctor visit by offering patients a free virtual consultation that can result in a prescription for neffy. Eligible patients with commercial insurance may qualify for a $0 co-pay, making it easier and more affordable to obtain the medication.

Richard Lowenthal, Co-founder, President, and CEO of ARS Pharma, highlighted the growing demand for convenient care options among allergy patients. With about 40 million Americans affected by severe allergies and limited access to allergists, more than 70% of Type 1 allergy patients expressed openness to virtual prescribing. The program aims to meet this need, enabling patients to receive prescriptions efficiently and access neffy within days through local pharmacies or home delivery.

The “Get neffy on Us” initiative complements ARS Pharma’s broader mission to increase the availability of needle-free allergy treatments. It follows the successful “neffyInSchools” program, which has already supplied more than 6,600 schools across 20 U.S. states with free neffy packs to manage severe allergic emergencies, reinforcing the company’s commitment to public health and allergy safety.